Obayda Azizy

Dr. Obayda Azizy

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2026 in Journal of Interventional Cardiology
Verified
Journal Article
Open access
OAObayda Azizy
Obayda Azizy
AAA. Alwakaa
A. Alwakaa
JTJ. Trippe
J. Trippe
MSMartin Steinmetz
Martin Steinmetz
MOM. K. Oezcueruemez
M. K. Oezcueruemez
PPP. C. Patsalis
P. C. Patsalis
Introduction: Cardiac implantable electronic device (CIED) infections remain a significant clinical challenge, particularly in high‐risk populations. In view of their severity, a re‐evaluation of preventive strategies is warranted. Real‐world evidence on the procedural safety of a gentamicin‐containing hemostatic collagen sponge (GS) for pocket prophylaxis is limited. Methods: We conducted a retrospective single‐center analysis of consecutive CIED implantations between October 2022 and October 2024 ( n = 143). Perioperative prophylaxis consisted of intravenous ceftriaxone 2 g; in patients with documented β ‐lactam allergy, intravenous clindamycin was administered. In addition, a gentamicin‐containing hemostatic collagen sponge was placed in the device pocket. Outcomes included procedural success, local and systemic complications, inflammatory markers, transesophageal echocardiography (TEE) for endocarditis, and CIED‐related infection during the 12‐month follow‐up. Results: The mean age was 74.5 years (SD ± 12), with males comprising 58% of the study population. Comorbidities were frequent (hypertension 81.1%, coronary artery disease 56%, heart failure 33%, diabetes mellitus 27%, renal failure 11%, and COPD 5.6%). Among patients, 5.6% were immunocompromised. Devices included dual‐chamber pacemakers (74.8%), single‐chamber pacemakers (10.5%), implantable cardioverter‐defibrillators (10.5%), and event recorders (4.2%). Lead configuration was one lead in 17%, two leads in 74.5%, and three leads in 8.5%. Procedural success was 99.3%, with one lead dislodgement. Postoperative inflammatory markers remained within normal limits (CRP: 1.93 ± 3.82 mg/L; median: 0.51 mg/L; leukocytes: 7.87 ± 2.49 × 10^9/L; procalcitonin: 0.138 ± 0.11 ng/mL; n = 13), and no pathological fevers occurred. No clinically adjudicated CIED infections (major or minor) were observed during the 12‐month follow‐up. Clinical signs of pocket infection were absent in 142/143 patients (99.3%). One patient (0.7%) developed a pocket hematoma with localized tenderness while under intensive immunosuppression. Postprocedure TEE detected no endocarditis. Conclusion: In this exploratory cohort, adjunctive gentamicin–collagen sponge use demonstrated procedural feasibility without early safety signals. These findings are descriptive and hypothesis‐generating. Given the retrospective design, absence of a control group, limited sample size, and zero‐event outcome, causal effectiveness cannot be established. Prospective multicenter studies with larger cohorts and longer follow‐up are warranted to define effectiveness, durability, and appropriate patient selection.

10 June 2026 in JACC: Case Reports
Verified
Journal Article
Open access
MNMohamad Amer Nashtar
Mohamad Amer Nashtar
MSMartin Steinmetz
Martin Steinmetz
ASAndreas Schnitzbauer
Andreas Schnitzbauer
PPPolykarpos Christos Patsalis
Polykarpos Christos Patsalis
OAObayda Azizy
Obayda Azizy
Right atrial (RA) thrombi are rare, potentially fatal, and lack standardized interventional treatment strategies. A 52-year-old dialysis-dependent woman with type 1 diabetes and prior pancreas and kidney transplantation presented with catheter-related sepsis. Transesophageal echocardiography and cardiac magnetic resonance imaging revealed a large RA thrombus (4 × 2 cm) in contact with the tricuspid valve. The infected dialysis catheter was removed. Given prohibitive surgical risk, percutaneous aspiration using the FlowTriever system was performed, resulting in near-complete thrombus removal. A small residual thrombus was managed with systemic anticoagulation. Follow-up imaging demonstrated complete thrombus resolution at 1 year. This case demonstrates the potential feasibility of large-bore aspiration thrombectomy for RA thrombi in high-risk patients and highlights the role of multimodality imaging in diagnosis and follow-up. Percutaneous aspiration thrombectomy may offer a viable alternative to surgery for selected patients with large RA thrombi.

10 June 2026 in JACC: Case Reports
Verified
Journal Article
Open access
MNMohamad Amer Nashtar
Mohamad Amer Nashtar
MSMartin Steinmetz
Martin Steinmetz
JTJörn Trippe
Jörn Trippe
PPPolykarpos Christos Patsalis
Polykarpos Christos Patsalis
OAObayda Azizy
Obayda Azizy
Atrial fibrillation (AF) increases the risk of thromboembolic events, most commonly owing to thrombus formation in the left atrial appendage (LAA). Anticoagulation reduces thromboembolic risk but increases bleeding risk. Congenital absence of the LAA is a rare anatomical variant that may influence anticoagulation strategies. A 78-year-old man with permanent AF and recurrent obscure gastrointestinal bleeding was evaluated for potential LAA occlusion. Transesophageal echocardiography and cardiac magnetic resonance imaging demonstrated congenital absence of the LAA without evidence of atrial thrombus. Considering the patient's high bleeding risk, anticoagulation therapy was discontinued after multidisciplinary assessment. No cardiac thrombus formation was detected on imaging at 6 months, and the patient remained clinically free of thromboembolic events at 18 months. This case illustrates the importance of multimodal imaging in identifying congenital LAA absence and guiding individualized anticoagulation decisions. Congenital LAA absence may allow individualized reconsideration of anticoagulation in selected AF patients with high bleeding risk.

13 April 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
OAObayda Azizy
Obayda Azizy
AAAhmad Alwakaa
Ahmad Alwakaa
MAMussab Alali
Mussab Alali
Mohamad Amer NashtarMohamad Amer Nashtar
Mohamad Amer Nashtar
MGMortimer Gierthmuehlen
Mortimer Gierthmuehlen
PPPolykarpos Christos Patsalis
Polykarpos Christos Patsalis
Background/Objectives: Atrial fibrillation is the most common sustained arrhythmia and frequently occurs in the perioperative setting. However, its clinical relevance in neurosurgical patients remains poorly defined despite increased vulnerability related to brain injury, inflammation, and perioperative stress. This study aimed to determine whether newly detected postoperative atrial fibrillation (POAF) identifies a higher-risk profile and is associated with postoperative complications, resource utilization, and short-term mortality compared with patients remaining in sinus rhythm (SR). Methods: We conducted a single-center retrospective cohort study (October 2020–April 2025). Among 2619 neurosurgical procedures, only patients with both pre- and in-hospital post-procedure ECGs and no pre-existing arrhythmia were included. POAF was defined as atrial fibrillation detected on any post-procedure ECG. Outcomes were compared using Welch’s t-test, χ2/Fisher’s exact tests, and odds ratios (OR) with 95% confidence intervals (CI). This study was not designed to estimate the incidence of POAF but rather to compare outcomes within a selected ECG-screened subgroup. Results: A total of 171 patients met the inclusion criteria: 79 (46.2%) developed POAF and 92 (53.8%) remained in SR. Patients with POAF were older and had a higher burden of cardiometabolic comorbidities and were more likely to undergo craniotomy/trepanation and emergency procedures. Compared with SR, POAF was associated with higher rates of postoperative complications, longer ICU and hospital stay, lower likelihood of discharge home, and higher short-term mortality. These findings reflect a selected ECG-screened cohort and should not be interpreted as the incidence of POAF in the overall neurosurgical population. Conclusions: Newly detected POAF is associated with a higher-risk postoperative profile in neurosurgical patients. It clusters with greater comorbidity burden, more invasive and urgent procedures, increased complications, prolonged hospitalization, reduced likelihood of discharge home, and higher short-term mortality. These findings support further evaluation of rhythm surveillance and perioperative management strategies in higher-risk neurosurgical populations.

27 October 2026 in Medical Sciences
Verified
Journal Article
Open access
PDF file
PIPanagiotis Iliakis
Panagiotis Iliakis
ASAthanasios Sakalidis
Athanasios Sakalidis
Nikolaos KtenopoulosNikolaos Ktenopoulos
Nikolaos Ktenopoulos
Anastasios ApostolosAnastasios Apostolos
Anastasios Apostolos
PKPaschalis Karakasis
Paschalis Karakasis
KTKonstantinos Tsioufis
Konstantinos Tsioufis
Percutaneous coronary intervention (PCI) effectively treats flow-limiting coronary lesions but does not eliminate the systemic processes that drive atherosclerotic progression and recurrent events. Residual inflammatory risk (RIR), most commonly identified by persistent elevation of high-sensitivity C-reactive protein (hsCRP), has emerged as an important component of this remaining risk and frequently persists despite intensive lipid lowering. Its interpretation after PCI, however, requires attention to timing, since inflammation related to acute myocardial injury and procedural vascular damage must be distinguished from persistent inflammatory activity after clinical stabilisation. In this review, we examine the biological basis of RIR and its relationship with plaque vulnerability, vascular healing, and recurrent events after coronary intervention. We discuss the role of hsCRP and other circulating biomarkers in post-PCI phenotyping, together with cardiometabolic conditions—including obesity, diabetes, chronic kidney disease, atherogenic dyslipidaemia, and hyperuricaemia—that may sustain inflammatory activation despite successful revascularisation. We also critically appraise the therapeutic evidence. Although CANTOS established inflammation as a modifiable component of atherothrombotic risk and colchicine has shown benefit in selected coronary populations, neutral findings with hyperacute colchicine initiation and, more recently, IL-6 inhibition emphasise that biomarker reduction does not necessarily translate into fewer cardiovascular events. Current guidelines recognise anti-inflammatory therapy in selected settings but do not recommend hsCRP-guided treatment after PCI. RIR therefore represents a clinically relevant post-PCI risk phenotype, but its transition from prognostic marker to actionable treatment target will require better definition of timing, inflammatory pathways, and the patients most likely to benefit from intervention.

30 July 2026 in Medicina
Verified
Journal Article
Open access
PDF file
PIPanagiotis Iliakis
Panagiotis Iliakis
KNKonstantina Ntalekou
Konstantina Ntalekou
ESEleftheria Stamou
Eleftheria Stamou
AKAikaterini-Eleftheria Karanikola
Aikaterini-Eleftheria Karanikola
AMAndreas Mavroudis
Andreas Mavroudis
KTKonstantinos Tsioufis
Konstantinos Tsioufis
Acute coronary syndrome (ACS) remains a leading cause of cardiovascular morbidity and mortality worldwide. Although traditional cardiovascular risk factors remain central to ACS development, recreational drug use is increasingly recognized as a clinically relevant trigger, particularly in younger patients with fewer conventional risk factors. This narrative review synthesized evidence identified through searches of PubMed/MEDLINE and Scopus up to June 2026, including clinical guidelines, systematic reviews, observational studies, mechanistic investigations, and clinically informative case-based evidence. Cannabis, cocaine, amphetamines, methamphetamine, 3,4-methylenedioxymethamphetamine (MDMA), opioids, lysergic acid diethylamide (LSD), synthetic cannabinoids, and polysubstance use may promote myocardial ischemia and infarction through overlapping mechanisms, including sympathetic activation, coronary vasospasm, endothelial dysfunction, oxidative stress, inflammation, platelet activation, thrombosis, arrhythmogenesis, and myocardial oxygen supply–demand mismatch. Clinical presentation may be typical or atypical and may overlap with intoxication, withdrawal, anxiety, neurological symptoms, or non-cardiac chest pain, making diagnosis challenging. Underreporting of recreational drug use is common, and targeted toxicology screening may improve diagnostic accuracy and risk stratification, particularly in patients younger than 50 years, those with few traditional cardiovascular risk factors, or those presenting with otherwise unexplained ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), coronary vasospasm, arrhythmias, or cardiac arrest. Acute management should generally follow standard ACS guidelines, while considering drug-specific issues such as stimulant-induced vasospasm, sympathetic excess, cautious use of beta-blockers during acute intoxication, and preference for primary percutaneous coronary intervention when fibrinolysis carries increased risk. Long-term care should combine evidence-based secondary prevention with substance-use counseling, addiction medicine referral, cardiac rehabilitation, and behavioural interventions. This review summarizes the pathophysiology, clinical manifestations, epidemiology, treatment considerations, preventive strategies, and knowledge gaps related to recreational drug-associated ACS.